![]() ![]() Silverback Therapeutics is located in Seattle, Washington. The talented and fun Silverback Therapeutics CMC team is looking for a great CMC project manager who is ready to make key contributions to a thriving small company focused on improving the lives. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Members of the Silverback management team will also host investor meetings during the conference. SEATTLE- ( BUSINESS WIRE )-Silverback Therapeutics Inc. Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will participate in the “Heavenly (anti)Bodies” panel on Tuesday, Augat 1:10 p.m. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021. Philadelphia (PA): AACR Cancer Res 2019 79(13 Suppl):Abstract nr 3271.SEATTLE-( BUSINESS WIRE)-Silverback Therapeutics, Inc. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019 2019 Mar 29-Apr 3 Atlanta, GA. A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors. Smith, Hengyu Xu, Ben Setter, Li-Qun Fan, Rebecca Brunette, Justin Killebrew, Phil Tan, Craig Coburn, Peter Baum, Valerie Odegard. More broadly, the data presented here describe a novel therapeutic modality that allows for systemic administration of immune modulators with tissue-localized activity.Ĭitation Format: Kara Moyes, Ty Brender, Sean W. Silverback’s lead candidate, SBT6050, is currently in preclinical development for patients with moderate or high HER2-expressing tumors. ![]() In contrast to observations with small molecule TLR8 agonists, ImmunoTAC does not induce peripheral cytokine production or associated CRS-like toxicity in mice, consistent with the localized activity of the molecule. Kunszabo Canale Communications (619) 849-5392. Mice cured with single-agent treatment are resistant to tumor rechallenge, demonstrating induction of long-lived immunological memory. Silverback Therapeutics is located in Seattle, Washington. Seattle, WA 7,797 followers Follow View all 12 employees Report this company Overview Jobs Life There are currently no jobs posted at Silverback Therapeutics. The intratumoral immune response is characterized by robust activation of tumor-associated myeloid cells, infiltration of neutrophils, persistent increases in local cytokine and chemokine production, decreases in Treg infiltrate, and the generation of a potent, neo-Ag specific anti-tumor CTL response. Systemic delivery of a SBT6050 surrogate in mice shows robust single agent efficacy in tumor models intrinsically resistant to checkpoint blockade, such as the previously characterized HER2+ CT26 syngeneic model. Additionally, SBT6050 potently activates conventional dendritic cells that, in turn, drive a Th1/CTL program in T cells. Seattle, Washington 98109 (206) 456-2900 (Name, address, including zip code and telephone number, including area code, of agent for service) Copies to: Kenneth J. This activity is dependent upon the ability of the Fc domain of the antibody to engage Fcγ receptors on the surface of the myeloid cells. SBT6050 is designed to activate human monocytes and macrophages only in the presence of HER2 pos tumor cells with moderate (2+ by IHC) or high (3+ by IHC) expression levels. SBT6050 is an ImmunoTAC comprised of a novel, potent TLR8 agonist conjugated to a HER2-directed monoclonal antibody. Agonism of TLR8 in human myeloid cells drives anti-tumor immunity by inducing direct macrophage killing of tumor cells, repolarizing suppressive myeloid cell populations to a pro-immunogenic phenotype, and inducing dendritic cells to drive tumor-specific CTL responses. Here, we describe an example of a new composition class, termed ImmunoTAC, that allows for systemic delivery of an immune modulator with activity localized to tumor sites and secondary lymphoid structures. Intratumoral administration, the route of delivery typically used for innate immune/myeloid cell agonists, is limited by tumor accessibility and a dependence on abscopal responses. Clinical development of systemically administered myeloid cell agonists has been hindered by acute toxicities due to peripheral activation of the targeted cell types.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |